During July-March, Bangladesh’s top pharmaceutical firms exhibited impressive financial results, despite economic challenges. IBN Sina Pharma led with a remarkable 26% year-on-year revenue growth, reaching Tk837 crore. Navana Pharma and ACME Laboratories followed closely, with 19% revenue growth each, reaching Tk503 crore and Tk2,353 crore, respectively. Square Pharma, a leading player, secured a notable 13% revenue growth, reaching Tk6,286 crore, the highest among peers. Renata and Beximco Pharma saw revenue increases of 14% (Tk2,781 crore) and 13% (Tk3,305 crore), respectively.
Despite high inflation, which constrained consumer spending, the pharmaceutical sector thrived due to increased demand for medicines. However, Square Pharma, ACME Laboratories, and Renata faced inflation-related challenges, leading to heightened expenditures on raw materials. Square Pharma’s profit rose by 9% to Tk1,464 crore, ACME Laboratories saw a 7% growth to Tk180 crore, while Renata’s profit declined by 4% to Tk258 crore. Only Beximco Pharma, IBN Sina Pharma, and Navana Pharma posted double-digit profit growth.
Source for more details:
